With the clock ticking away on a two-month reprieve from the deficit-reducing sequestration, the White House is warning the FDA, National Institutes of Health (NIH) and other government agencies to prepare to be chopped. Read More
It may be a bad environment for early stage deals for most companies. But not for start-up EnBiotix Inc., according to its CEO Jeffrey Wager. The company, which was founded in 2012, is "in discussions with multiple pharma companies" for partnering opportunities. Read More
Riding high after laying to rest its patent skirmish, Alnylam Pharmaceuticals Inc. priced its public offering of 8 million shares without a discount, selling them at Tuesday's closing price of $21.32, for net proceeds of about $151.1 million, or about $173.8 million if the underwriters exercise their full overallotment option of 1.2 million shares. Read More
• Cardium Therapeutics Inc., of San Diego, said the NYSE Amex LLC accepted an exchange listing compliance plan from the company after it was notified that it was not in compliance with one of the exchange's listing requirements based on its third-quarter 2012 report. Read More
• Stratatech Corp., of Madison, Wis., reported top-line data from a proof-of-concept trial testing StrataGraft, a universal human skin substitute in development for treating severe burns. Read More
• Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations. Read More
• Curis Inc., of Lexington, Mass., was issued U.S. Patent No. 8,324,240, "Fused Amino Pyridine as HSP90 Inhibitors," for a genus of compounds, which include Debio 0932, a heat-shock protein 90 inhibitor. Read More
